CheckMate-67T: Subcutaneous Nivolumab Shows Comparable Results to IV, Reduces Treatment Burden in RCC - Saby George
Saby George
Dan George discusses the CheckMate-67T study with Saby George, a phase three trial comparing intravenous and subcutaneous administration of nivolumab in treatment-refractory kidney cancer patients.